Impairment of mitochondrial energy metabolism has been associated with a wide range of human disorders. MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes) is a relatively common mitochondrial phenotype frequently associated with a point mutation at nucleotide 3243 of the mitochondrial DNA (m.3243A>G), and characterized clinically by progressive neurological decline, multisystem medical problems, and premature death. Over the past 15 years, our team has conducted a large-scale, longitudinal follow-up study in a cohort of MELAS/3243 patients, which has enabled us to establish a strong foundation in terms of data, outcome measures and infrastructure for conducting clinical trials of promising therapeutic agents,, none of which - sadly - has proved effective. Thus, MELAS patients remain without treatment options. To address this unmet need, our primary aim is to conduct a Phase 11/111, multi-center, randomized, placebo controlled clinical trial of SNT-MC17/idebenone, with a statistical global test of health status as primary outcome consisting of 1) neurological event count, 2) daily living functional abilities, 3) neurological exam, and 4) neuropsychological testing. SNT-MC17/idebenone has emerged as highly promising treatment for MELAS because it is a powerful antioxidant and a modulator of adenosine triphosphate (ATP) production and because it has been reported beneficial in a number of mitochondrial disorders including MELAS, Leber's hereditary optical neuropathy (LHON), and Friedreich's Ataxia. We postulate that the clinical effects of SNT-MC17/idebenone will be mediated by improvements of oxidative energy metabolism. To derive objective measures of a treatment effect, we propose to determine in vivo levels of lactate in the cerebral occipital lobe during photic stimulation by [1]H magnetic resonance spectroscopic imaging ([1]H-MRSI) and levels of high-energy phosphates by dynamic [31]P-MRSI, in the calf muscle during exercise. Given the lack of long-term follow-up studies in patients with MELAS/3243, our Specific Aim 3 is to continue collecting longitudinal data on subjects enrolled in our ongoing cohort study.

Public Health Relevance

Our proposal is relevant to three key needs for MELAS/3243 patients. First, it evaluates a promising treatment in a controlled trial, which could ameliorate this devastating disease and reduce the individual and societal burden of MELAS/3243. Second, the proposed MRSI studies of a potential biomarker can provide mechanistic insights into the consequences of idebenone treatment and serve as an early efficacy read-out in future trials, thus potentially accelerating drug development. Third, we will gather long-term follow-up data on our MELAS/3243 cohort, addressing crucial questions that all patients have regarding their prognosis.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHD1-MRG-C)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University
New York
United States
Zip Code
Barca, Emanuele; Ganetzky, Rebecca D; Potluri, Prasanth et al. (2018) USMG5 Ashkenazi Jewish founder mutation impairs mitochondrial complex V dimerization and ATP synthesis. Hum Mol Genet 27:3305-3312
Pera, Marta; Larrea, Delfina; Guardia-Laguarta, Cristina et al. (2017) Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease. EMBO J 36:3356-3371
Fryer, Robert H; Bain, Jennifer M; De Vivo, Darryl C (2016) Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-Like Episodes (MELAS): A Case Report and Critical Reappraisal of Treatment Options. Pediatr Neurol 56:59-61
Varma, Hemant; Faust, Phyllis L; Iglesias, Alejandro D et al. (2016) Whole exome sequencing identifies a homozygous POLG2 missense variant in an infant with fulminant hepatic failure and mitochondrial DNA depletion. Eur J Med Genet 59:540-5
Piekutowska-Abramczuk, Dorota; Kocy?a-Karczmarewicz, Beata; Ma?kowska, Maja et al. (2016) No Evidence for Association of SCO2 Heterozygosity with High-Grade Myopia or Other Diseases with Possible Mitochondrial Dysfunction. JIMD Rep 27:63-8
Cloonan, Suzanne M; Glass, Kimberly; Laucho-Contreras, Maria E et al. (2016) Mitochondrial iron chelation ameliorates cigarette smoke-induced bronchitis and emphysema in mice. Nat Med 22:163-74
Engelstad, Kristin; Sklerov, Miriam; Kriger, Joshua et al. (2016) Attitudes toward prevention of mtDNA-related diseases through oocyte mitochondrial replacement therapy. Hum Reprod 31:1058-65
Ripolone, Michela; Ronchi, Dario; Violano, Raffaella et al. (2015) Impaired Muscle Mitochondrial Biogenesis and Myogenesis in Spinal Muscular Atrophy. JAMA Neurol 72:666-75
Paradas, Carmen; Akman, Hasan O; Ionete, Carolina et al. (2014) Branching enzyme deficiency: expanding the clinical spectrum. JAMA Neurol 71:41-7
Garcia-Diaz, Beatriz; Garone, Caterina; Barca, Emanuele et al. (2014) Deoxynucleoside stress exacerbates the phenotype of a mouse model of mitochondrial neurogastrointestinal encephalopathy. Brain 137:1337-49

Showing the most recent 10 out of 241 publications